

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

215869US0PCT

SERIAL NO.

09/926,641

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Nobuya MATSUOKA, et al.

FILING DATE

November 28, 2001

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

COPY

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
✓	AO	98 25914 ✓	06/18/98	WO		No
✓	AP	00 42011 ✓	07/20/00	WO		No
✓	AQ	98 35951 ✓	08/20/98	WO		No
✓	AR	0 436 734 ✓	07/17/91	EP		No
✓	AS	97 36871 ✓	10/09/97	WO		No
✓	AT	99 55674 ✓	11/04/99	WO		No
	AU					
	AV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

✓	AW	Nobuya MATSUOKA et al.: "FK960 'N-(4-acetyl-1-piperazinyl)-p-fluorobenzam antideementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine" J. PHARMACOL. EXP. THER., 280(3), pages 1201-1209 1997 ✓
✓	AX	A. GRAUL et al.: "FK-960. Cognition enhancer." DRUGS FUTURE, 22(8), pages 830-832 1997 ✓
✓	AY	Nobuya MATSUOKA et al.: "FK960, a novel potential anti-dementia drug, augments long-term potentiation in mossy fiber-CA3 pathway of guinea-pig hippocampal slices" BRAIN RESEARCH, vol. 794, no. 2, pages 248-254 06/01/98 ✓
	AZ	

☐ Additional References sheet(s) attached

Examiner

Raymond Conita

Date Considered

9/29/04

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.